Indacaterol onset of action versus placebo and active controls in moderate to severe COPD

Phase 3, randomised, triple-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Novartis. Primary endpoint: FEV1 at 5 minutes post-dose for indacaterol 150 or 300 micrograms versus placebo. Started Feb 2008; status: completed.